Bilateral Synchronous Carcinoma of the Male Breast in a Patient Receiving Estrogen Therapy for Carcinoma of the Prostate: Cause or Coincidence?

Coard, K. C. M.; T, McCartney

doi:10.1097/01.smj.0000050686.54786.79

Cited by 18 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both are hormonal responsive tumours. According to several reports long term use of anti-androgens and oestrogens in the treatment of prostatic cancer has resulted in MBC (Dicker et al, 2003;Thellenberg et al, 2003;Coard et al, 2004;Chianakwalam et al, 2005). External radiation has been associated with a few cases of MBC, for the treatment of Hodgkin's disease (Cutuli et al, 2001).…”

Section: Risk Factorsmentioning

confidence: 99%

Male Breast Carcinoma: Epidemiology, Risk Factors and Current Therapeutic Approaches

Zygogianni

Kyrgias²,

Gennatas³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Male breast cancer is a very rare disease with an incidence of about 0.5-1% comparing with the one of female breast cancer but relatively little is known about its cause. Treatment strategies for breast cancer in males are derived from studies performed among females. The probable reasons behind the frequent, late diagnoses presented at stages III or IV might be the lack of awareness. The rarity of the disease precludes large prospective randomized clinical trials. This study reviews male breast cancer and its risk factors, recommendations for diagnosis and the management of patients with male breast cancer.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Male Breast Carcinoma: Epidemiology, Risk Factors and Current Therapeutic Approaches

Zygogianni

Kyrgias²,

Gennatas³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…27 The prevalence of bilateral breast cancer is 1.4% of all cases in men, with synchronous involvement accounting for only one-third of those. 28 To our knowledge, there have been only fi ve previously reported cases of synchronous bilateral breast cancer after hormone therapy (Table 1). In 1949, Howard et al 29 reported a case of microscopically proven bilateral scirrhous carcinoma of the male breast in a patient treated for carcinoma of the prostate with a total of 40 280 mg of diethylstilbestrol.…”

Section: Discussionmentioning

confidence: 92%

Synchronous bilateral breast cancer in a male patient following hormone therapy for prostate cancer

et al. 2009

View full text Add to dashboard Cite

We report an unusual case of bilateral, synchronous breast cancer in a male patient who had a history of estrogen therapy for prostate cancer. A 64-year-old Japanese man was diagnosed with T1N0M0 prostate cancer and received a total prostatectomy. Twenty months after the resection, the patient developed multiple bone metastases, and received radiation therapy, systemic chemotherapy, and hormone therapy for 15 months. After completing this treatment, he was diagnosed with T1N0M0 primary breast cancer in his left breast and underwent a modified mastectomy. Five months after the mastectomy he received systemic chemotherapy followed by estrogen therapy because of the progression of prostate cancer. Three months after this treatment, he was diagnosed with T1N0M0 primary breast cancer in his right breast. To the best of our knowledge, this is a rare case of synchronous bilateral male breast cancer following hormone therapy for prostate cancer.

show abstract

“…It has been hypothesized that there is a relationship between male breast cancer and administration of serotonin reuptake inhibitors [19]. Another factor postulated in the pathogenesis of breast carcinoma in men is an excessive exposition to estrogens (of endogenous and exogenous origin) [20]. It includes hiperestrogenism in Klinefelter syndrome, estrogen/androgen imbalance in the diseases of the liver, kidney and circulatory system, in adiposity, alcohol abuse or during therapy with antiandrogens (spironolactone, cimetidine, finasteride) [7,[21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Breast cancer and long-term hormonal treatment of male hypogonadism

Mędraś

Filus

Jóźków

et al. 2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer in men is rare and its etiology is multifactorial. Androgens may promote the development of breast carcinoma in men though data on the subject is scarce. We observed 45 men with hypergonadotropic hypogonadism (aged 18-57) who received 250 mg of testosterone esters (Omnadren 250, Jelfa, Poland) every 3-4 weeks for 5-26 years. Seventeen of them were treated for more than 10 years. During the observation period breast cancer was diagnosed in 2 subjects (11% of the followed men). In one case it occurred after 11 years and in the other after 15 years of the therapy. We point to a possible association between long-term androgen replacement and a risk of breast cancer in men.

show abstract

Bilateral Synchronous Carcinoma of the Male Breast in a Patient Receiving Estrogen Therapy for Carcinoma of the Prostate: Cause or Coincidence?

Abstract: An unusual case of bilateral, synchronous breast cancer in a male patient who had a history of long-term estrogen therapy for prostate cancer is presented. The possible role of estrogen in the development of male breast cancer is revisited.

Cited by 18 publications

References 17 publications

Male Breast Carcinoma: Epidemiology, Risk Factors and Current Therapeutic Approaches

Male Breast Carcinoma: Epidemiology, Risk Factors and Current Therapeutic Approaches

Synchronous bilateral breast cancer in a male patient following hormone therapy for prostate cancer

Breast cancer and long-term hormonal treatment of male hypogonadism

Contact Info

Product

Resources

About